EUPATI project will provide cancer patients’ with scientifically reliable, objective and comprehensive information
21 Feb 2012
The European Patients’ Academy on Therapeutic Innovation (EUPATI) project is a consortium of 29 organizations led by the European Patients’ Forum and including the EORTC among others. EUPATI aims to provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical research and development and increase the capacity of well-informed patients to be effective advocates and advisors, for example in clinical trials, with regulatory authorities and in ethics committees.
Development of medicines is a complicated process. It is highly regulated, expensive, and generally misunderstood by the general public. EUPATI plans to address these issues and improve the availability of information for patients. For example, EUPATI plan to develop and distribute user-friendly educational modules concerning therapeutic innovations, build upon the competencies of well informed patients and the public about pharmaceutical research and development, and facilitate patient involvement in all facets of drug development.
The first public meeting of the European Patients’ Academy on Therapeutic Innovation will be held during the Drug Information Association EuroMeeting on 27 March 2012 from 14:00-16:00 in Copenhagen.
http://www.patientsacademy.eu/index.php/en/news/13-eupati-launch-cp
You can learn more about EUPATI on their website, or follow them online:
www.facebook.com/patientsacademy.eu
Twitter: @eupatients
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023